Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus TERAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus TERAZOSIN HYDROCHLORIDE.
FLOMAX vs TERAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker